, Association pour la Recherche contre le Cancer' (contract AO/3/5099) G Gadea, N Arsic and P Roux are supported by CNRS and INSERM. Additional information Funding Funder Grant reference number Author Centre National de la Recherche Scientifique Gilles Gadea Nikola Arsic Pierre Roux, p.5099

P. Marie, . Khoury-breast-cancer-campaign, and . Bcc,

, The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication

G. Author-contributions, N. Kf, . Ad, . Smj, . Sa et al., Acquisition of data, Analysis and interpretation of data, Drafting or revising the article; SV, CA, Acquisition of data, Analysis and interpretation of data, Contributed unpublished essential data or reagents; MdT, MC, Acquisition of data; AMT, Conception and design, Analysis and interpretation of data, Drafting or revising the article ; J-CB, PR, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article, pp.0-0001

J. Bourdon, , pp.0-0003

P. Roux,

, Ethics Human subjects: Samples were examined following Local Research Ethics Committee approval under delegated authority by the Tayside Tissue Bank (www.taysidetissuebank.org)

, References

M. Adorno, M. Cordenonsi, M. Montagner, S. Dupont, C. Wong et al., A Mutant-p53/Smad Complex Opposes p63 to Empower TGF??-Induced Metastasis, Cell, vol.137, issue.1, pp.87-98, 2009.
DOI : 10.1016/j.cell.2009.01.039

M. Aoubala, F. Murray-zmijewski, M. Khoury, K. Fernandes, S. Perrier et al., p53 directly transactivates ??133p53??, regulating cell fate outcome in response to DNA damage, Cell Death & Differentiation, vol.101, issue.2, pp.248-258, 2011.
DOI : 10.1016/0027-5107(93)90162-9

URL : https://hal.archives-ouvertes.fr/inserm-00840976

N. Arsic, N. Bendris, M. Peter, C. Begon-pescia, C. Rebouissou et al., A novel function for Cyclin A2: Control of cell invasion via RhoA signaling, The Journal of Cell Biology, vol.113, issue.1, pp.147-162, 2012.
DOI : 10.1074/jbc.M406082200

URL : https://hal.archives-ouvertes.fr/hal-00714616

N. Arsic, G. Gadea, E. Lagerqvist, M. Busson, N. Cahuzac et al., The p53 isoform D133p53b promotes cancer stem cell potential, Stem Cell Reports, vol.4, p.25754205, 2015.

H. Bernard, B. Garmy-susini, N. Ainaoui, L. Van-den-berghe, A. Peurichard et al., The p53 isoform, ??133p53??, stimulates angiogenesis and tumour progression, Oncogene, vol.122, issue.17, pp.2150-2160, 2013.
DOI : 10.1002/ijc.23313

URL : https://hal.archives-ouvertes.fr/inserm-00714607

H. Bloom and W. Richardson, Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years, British Journal of Cancer, vol.11, p.13499785, 1957.

J. Bourdon, K. Fernandes, F. Murray-zmijewski, G. Liu, A. Diot et al., p53 isoforms can regulate p53 transcriptional activity, Genes & Development, vol.19, issue.18, pp.2122-2137, 2005.
DOI : 10.1101/gad.1339905

J. Bourdon, M. Khoury, A. Diot, L. Baker, K. Fernandes et al., p53 mutant breast cancer patients expressing p53g have as good a prognosis as wild-type p53 breast cancer patients, Breast Cancer Research, vol.13, pp.10-1186, 2011.

R. Brosh and V. Rotter, When mutants gain new powers: news from the mutant p53 field, Nature Reviews Cancer, vol.276, issue.10, pp.701-713, 2009.
DOI : 10.7326/0003-4819-71-4-747

S. Camus, S. Mé-nendez, K. Fernandes, N. Kua, G. Liu et al., The p53 isoforms are differentially modified by Mdm2, Cell Cycle, vol.8, issue.8, pp.1646-1655, 2012.
DOI : 10.1038/nprot.2009.128

W. De-roock, B. Biesmans, D. Schutter, J. Tejpar, and S. , Clinical Biomarkers in Oncology, Molecular Diagnosis & Therapy, vol.15, issue.14, pp.103-114, 2009.
DOI : 10.1158/1078-0432.CCR-08-2961

S. Detre, S. Jotti, G. Dowsett, and M. , A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas., Journal of Clinical Pathology, vol.48, issue.9, pp.876-878, 1995.
DOI : 10.1136/jcp.48.9.876

P. Do, L. Varanasi, S. Fan, C. Li, I. Kubacka et al., Mutant p53 cooperates with ETS2 to promote etoposide resistance, Genes & Development, vol.26, issue.8, pp.830-845, 2012.
DOI : 10.1101/gad.181685.111

P. Dong, M. Tada, J. Hamada, A. Nakamura, T. Moriuchi et al., p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells, Clinical & Experimental Metastasis, vol.23, issue.6, pp.471-483, 2007.
DOI : 10.1128/MCB.14.3.1815

P. Friedl and K. Wolf, Tumour-cell invasion and migration: diversity and escape mechanisms, Nature Reviews Cancer, vol.3, issue.5, pp.362-374, 2003.
DOI : 10.1038/nrc1075

G. Gadea, M. De-toledo, C. Anguille, and P. Roux, Loss of p53 promotes RhoA???ROCK-dependent cell migration and invasion in 3D matrices, The Journal of Cell Biology, vol.11, issue.1, pp.17606-864, 2007.
DOI : 10.1083/jcb.150.4.797

G. Gadea, L. Roger, C. Anguille, M. De-toledo, V. Gire et al., TNF?? induces sequential activation of Cdc42- and p38/p53-dependent pathways that antagonistically regulate filopodia formation, Journal of Cell Science, vol.117, issue.26, pp.6355-6364, 2004.
DOI : 10.1242/jcs.01566

G. Gadé-a, L. Lapasset, C. Gauthier-rouviè-re, and P. Roux, Regulation of Cdc42-mediated morphological effects: a novel function for p53, The EMBO Journal, vol.21, issue.10, pp.2373-2382, 2002.
DOI : 10.1093/emboj/21.10.2373

A. Goldhirsch, E. Winer, A. Coates, R. Gelber, M. Piccart-gebhart et al., Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Annals of Oncology, vol.360, issue.Supp 1, pp.2206-2223
DOI : 10.1056/NEJMoa0810266

R. Hewitt, A. Mcmarlin, D. Kleiner, R. Wersto, P. Martin et al., Validation of a model of colon cancer progression, 9999<::AID-PATH775>3.0.CO;2-K, pp.446-454, 2000.
DOI : 10.1038/bjc.1995.55

J. Jackson, V. Pant, Q. Li, L. Chang, A. Quintá-s-cardama et al., p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer, Cancer Cell, vol.21, issue.6, pp.793-806
DOI : 10.1016/j.ccr.2012.04.027

D. Jenkins, Y. Hornig, Y. Oei, J. Dusich, and T. Purchio, Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivodetection of mammary tumors and multiple metastases in immune deficient mice, Breast Cancer Research, vol.2, issue.4, pp.444-454, 2005.
DOI : 10.1038/sj.neo.7900079

S. Joruiz and J. Bourdon, 2016. p53 Isoforms: Key regulators of the cell fate decision. Cold Spring Harbor Perspectives in Medicine 6:a026039, p.26801896

E. Kalo, Y. Buganim, K. Shapira, H. Besserglick, N. Goldfinger et al., Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor ??1 (TGF-??1) Signaling Pathway by Repressing the Expression of TGF-?? Receptor Type II, Molecular and Cellular Biology, vol.27, issue.23, pp.8228-8242, 2007.
DOI : 10.1128/MCB.00374-07

M. Suvà, N. Riggi, and B. Bernstein, Epigenetic Reprogramming in Cancer, Science, vol.12, issue.2, pp.1567-1570, 2013.
DOI : 10.1056/NEJMoa1008433

Y. Tang, I. Horikawa, M. Ajiro, A. Robles, K. Fujita et al., Downregulation of splicing factor SRSF3 induces p53??, an alternatively spliced isoform of p53 that promotes cellular senescence, Oncogene, vol.17, issue.22, pp.2792-2798, 2013.
DOI : 10.1128/JVI.01719-08

O. Terrier, V. Marcel, G. Cartet, D. Lane, L. B. Rosa-calatrava et al., Influenza A Viruses Control Expression of Proviral Human p53 Isoforms p53?? and ??133p53??, Journal of Virology, vol.86, issue.16, pp.8452-8460, 2012.
DOI : 10.1128/JVI.07143-11

J. Thiery, H. Acloque, R. Huang, and M. Nieto, Epithelial-Mesenchymal Transitions in Development and Disease, Cell, vol.139, issue.5, 2009.
DOI : 10.1016/j.cell.2009.11.007

S. Vinot, C. Anguille, M. De-toledo, G. Gadea, and P. Roux, Analysis of Cell Migration and Its Regulation by Rho GTPases and p53 in a Three???Dimensional Environment, Methods in Enzymology, vol.439, issue.07, pp.413-424, 2008.
DOI : 10.1016/S0076-6879(07)00429-6

URL : https://hal.archives-ouvertes.fr/hal-00347408